Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

APLS Apellis Pharmaceuticals Inc

33,21

0,07 (0,21%)

21 Dez 2024 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Apellis Pharmaceuticals Charts.

Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more Apellis Pharmaceuticals Charts.

News Apellis Pharmaceuticals Inc

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 13 Dezember 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 11 Dezember 2024 (1 Woche vor) • Edgar (US Regulatory)

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freitag 6 Dezember 2024 (2 Wochen vor) • GlobeNewswire Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Mittwoch 27 November 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 22 November 2024 (4 Wochen vor) • Edgar (US Regulatory)

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Dienstag 12 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Freitag 8 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Dienstag 5 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 5 November 2024 (2 Monate vor) • Edgar (US Regulatory)

U.S. Index Futures Rise as Election Looms; Oil and Gold Prices Steady
Dienstag 5 November 2024 (2 Monate vor) • IH Market News

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 1 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
Samstag 26 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere Apellis Pharmaceuticals Inc News-Artikel

Intesa Sanpaolo

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen